search
Back to results

Does Seasonal Influenza Vaccination Affect the Incidence of pH1N1 Influenza?

Primary Purpose

Influenza

Status
Completed
Phase
Phase 3
Locations
Canada
Study Type
Interventional
Intervention
Fluviral influenza vaccine, 2009-2010
Normal saline
Sponsored by
Mount Sinai Hospital, Canada
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional health services research trial for Influenza focused on measuring influenza, vaccine, observer blind

Eligibility Criteria

18 Years - 60 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  1. 18 to 60 years old, inclusive, as of September 1st, 2009;
  2. understand the study, agree to its provisions, and give written informed consent prior to entry;
  3. available for follow-up during the study period;
  4. have convenient access to a computer with internet access and basic skills for use of the internet;

Exclusion Criteria:

  1. planning to spend more than two consecutive weeks outside of Canada from October 1, 2009 to April 15th 2010.
  2. received immunoglobulin within six months of study entry;
  3. has already received a 2009 seasonal influenza vaccine (southern or northern hemisphere)
  4. has had laboratory-confirmed infection with 2009 H1N1 influenza
  5. is participating in a clinical trial that would result in the receipt of investigational medication during the study period;
  6. allergic to eggs, to influenza vaccine, or any components of the seasonal influenza vaccine
  7. has had a previous severe adverse event associated with an influenza vaccine
  8. has a significant chronic underlying illness that would warrant seasonal influenza vaccine in a usual year, or is known to be pregnant.

Sites / Locations

  • North York General Hospital
  • Mount Sinai Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Seasonal influenza vaccination

Placebo

Arm Description

Receipt of Fluviral seasonal (2009-2010, Canadian) influenza vaccination as per manufacturers specification

0.5 mL normal saline

Outcomes

Primary Outcome Measures

Number of pH1N1 Influenza Infections as Diagnosed by PCR From Mid-turbinate Swab
Influenza infection (pH1N1) as diagnosed by PCR from self-collected mid-turbinate swab. Participant is asked to collect a swab when they have symptoms possibly compatible with an acute viral respiratory illness: 1) fever without another obvious source, 2) at least two new respiratory symptoms (runny or stuffy nose, sneezing, sore or scratchy throat, hoarseness, cough), or 3) one respiratory symptom (as above) and one systemic symptom (fever, malaise, muscle aches, headache, fatigue)

Secondary Outcome Measures

Full Information

First Posted
October 23, 2009
Last Updated
April 18, 2012
Sponsor
Mount Sinai Hospital, Canada
Collaborators
GlaxoSmithKline
search

1. Study Identification

Unique Protocol Identification Number
NCT01001325
Brief Title
Does Seasonal Influenza Vaccination Affect the Incidence of pH1N1 Influenza?
Official Title
A Randomized Controlled Trial of the Effect of Seasonal Influenza Vaccination on the Incidence of Infection Due to the 2009 H1N1 Influenza
Study Type
Interventional

2. Study Status

Record Verification Date
April 2012
Overall Recruitment Status
Completed
Study Start Date
October 2009 (undefined)
Primary Completion Date
March 2010 (Actual)
Study Completion Date
July 2010 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Mount Sinai Hospital, Canada
Collaborators
GlaxoSmithKline

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Since the onset of the 2009 pandemic, several observational public health investigations in Canada have identified evidence that suggests that adults, particularly younger adults, who have previously received seasonal influenza vaccine are at increased risk of infection with the 2009 pandemic strain of H1N1 (pH1N1). Investigations in Australia, the United States and the United Kingdom have not identified this effect. While it is not possible to have an answer to whether this affect is real prior to the second wave of the 2009 pandemic, it remains vital to future influenza vaccination programs that the hypothesis that, in 2009, seasonal vaccine increases or decreases the risk of pH1N1 infection be confirmed or refuted. The objective of this study is to determine whether Ontario adults aged 18-60 years who receive the 2009 seasonal influenza vaccine will be at a 2 fold or greater increased risk of infection with influenza pH1N1 during the second or third wave of the 2009 pandemic.
Detailed Description
This study will be an observer -blind randomized controlled trial. This study will primarily recruit patients from an existing cohort of adult health care and other workers in Toronto, as of September 15, 2009, almost 1000 adults are participating in this cohort; with approximately 75 new cohort members being recruited weekly (target is 1300). Recruitment will be supplemented by enrollment at Hamilton Health Sciences Centre (N~3920 employees plus physicians & midwives) and Queen Elizabeth II Health Centre in Halifax (N~6000 employees plus physicians & midwives). To date, health care workers in the Toronto cohort have been recruited at the Mount Sinai Hospital, Toronto East General Hospital, and North York General Hospital. Recruitment is just beginning at Sunnybrook Health Sciences Centre, and the University Health Network. Non-health care workers are being recruited from several large Toronto employers of primarily office workers. These include the Ontario Agency for Health Protection and Promotion, the head offices of the Ontario Power Generation Corporation, the Art Gallery of Ontario, and the head offices of Scotia Bank. Non-health care workers should meet inclusion criteria and should not work primarily with children or from a home office. Participants in the study are completing web-based diaries weekly, and, whenever they develop symptoms possibly compatible with influenza, are submitting nasal swabs, and completing symptom diaries daily while ill. Nasal swabs are tested by polymerase chain reaction (PCR) on a same or next day basis with antivirals prescribed to participants who develop influenza.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Influenza
Keywords
influenza, vaccine, observer blind

7. Study Design

Primary Purpose
Health Services Research
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
468 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Seasonal influenza vaccination
Arm Type
Experimental
Arm Description
Receipt of Fluviral seasonal (2009-2010, Canadian) influenza vaccination as per manufacturers specification
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
0.5 mL normal saline
Intervention Type
Biological
Intervention Name(s)
Fluviral influenza vaccine, 2009-2010
Intervention Description
0.5 mL intramuscular
Intervention Type
Biological
Intervention Name(s)
Normal saline
Intervention Description
0.5 mL intramuscular
Primary Outcome Measure Information:
Title
Number of pH1N1 Influenza Infections as Diagnosed by PCR From Mid-turbinate Swab
Description
Influenza infection (pH1N1) as diagnosed by PCR from self-collected mid-turbinate swab. Participant is asked to collect a swab when they have symptoms possibly compatible with an acute viral respiratory illness: 1) fever without another obvious source, 2) at least two new respiratory symptoms (runny or stuffy nose, sneezing, sore or scratchy throat, hoarseness, cough), or 3) one respiratory symptom (as above) and one systemic symptom (fever, malaise, muscle aches, headache, fatigue)
Time Frame
day +7 post seasonal influenza vaccination (or placebo) to end of study

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: 18 to 60 years old, inclusive, as of September 1st, 2009; understand the study, agree to its provisions, and give written informed consent prior to entry; available for follow-up during the study period; have convenient access to a computer with internet access and basic skills for use of the internet; Exclusion Criteria: planning to spend more than two consecutive weeks outside of Canada from October 1, 2009 to April 15th 2010. received immunoglobulin within six months of study entry; has already received a 2009 seasonal influenza vaccine (southern or northern hemisphere) has had laboratory-confirmed infection with 2009 H1N1 influenza is participating in a clinical trial that would result in the receipt of investigational medication during the study period; allergic to eggs, to influenza vaccine, or any components of the seasonal influenza vaccine has had a previous severe adverse event associated with an influenza vaccine has a significant chronic underlying illness that would warrant seasonal influenza vaccine in a usual year, or is known to be pregnant.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Allison J McGeer, MD
Organizational Affiliation
MOUNT SINAI HOSPITAL
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Brenda L. Coleman, PhD
Organizational Affiliation
MOUNT SINAI HOSPITAL
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Natasha Crowcroft, MD
Organizational Affiliation
Ontario Agency for Health Protection & Promotion
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Karen Green, MSc
Organizational Affiliation
MOUNT SINAI HOSPITAL
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Kevin Katz, MD
Organizational Affiliation
North York General Hospital
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Mark Loeb, MD
Organizational Affiliation
Hamilton Health Sciences Centre
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Donald Low, MD
Organizational Affiliation
MOUNT SINAI HOSPITAL
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Shelly McNeil, MD
Organizational Affiliation
Queen Elizabeth II Health Sciences Centre
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Matthew Muller, MD, PhD
Organizational Affiliation
Unity Health Toronto
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Andrew Simor, MD
Organizational Affiliation
Sunnybrook Health Sciences Centre
Official's Role
Study Director
Facility Information:
Facility Name
North York General Hospital
City
North York
State/Province
Ontario
ZIP/Postal Code
M2K 1E1
Country
Canada
Facility Name
Mount Sinai Hospital
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M5G 1X5
Country
Canada

12. IPD Sharing Statement

Learn more about this trial

Does Seasonal Influenza Vaccination Affect the Incidence of pH1N1 Influenza?

We'll reach out to this number within 24 hrs